English
Back
Download
Log in to access Online Inquiry
Back to the Top

$Northwest Biotherapeutics (NWBO.US)$ Pat Sarma, appointed a...

$Northwest Biotherapeutics (NWBO.US)$ Pat Sarma, appointed as a Class II Director for Northwest Biotherapeutics (NW Bio) in March 2024, has made significant contributions as a positive catalyst for the company. One key accomplishment is his appointment as the Chairman of the Audit Committee and his membership in the Compensation and Conflicts Committees.
Sarma's extensive background as a business executive and venture capital investor, including founding American Megatrends Inc. (AMI), positions him as a valuable asset to NW Bio. Sarma's experience with AMI, which became a major player in the development of BIOS firmware and RAID technology, reflects his deep understanding of technological innovation and strategic growth. His prior investments in diverse industries, including medical and environmental companies, and his long-term investment in NW Bio, highlight his commitment to the company and its potential.
Sarma's insights and leadership are expected to support NW Bio's efforts in advancing its DCVax® personalized immune therapies for cancer, enhancing corporate governance, and driving future growth and innovation
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
5463 Views
Comment
Sign in to post a comment
    Just a trader who likes stocks, buying high and selling low. 🦧
    9
    Followers
    5
    Following
    26
    Visitors
    Follow
    Discussing
    Trump 2.0 Era: What's the next opportunity in the markets?
    ▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks Show More